Background: Our efforts, focused on the discovery of novel antiproliferative agents, led to the identification of an interesting oxadiazole derivative, MD77. Aim: To complete the studies concerning the antiproliferative profile of MD77 , we developed several new derivatives. Materials and Methods: The substitution pattern around the phenyl rings of this compound was analysed through the synthesis of positional isomers and of analogues bearing different substituents at the para positions (2-12). Results: The results of the antiproliferative activity of these derivatives versus HCT-116 and HeLa cancer cell lines shed light on the effects of the presence, nature and position of such substituents. Notably, derivative 4, a regioisomer of 1 in which the substituents at the para positions of the phenyl rings were inverted, showed the best antiproliferative profile, exhibiting a significant activity also against MCF7 and MDA-MB 468 cancer cell lines. Conclusion: Preliminary results showed the ability of compound 4 to counteract human recombinant topoisomerase II α relaxation activity.
Introduction
Cancer still ranks second behind cardiovascular diseases among the leading causes of death globally (1) and chemotherapy is the mainstay in the reduction of mortality. Nevertheless, anticancer drugs are generally extremely toxic, while their poor selectivity and the insurgence of resistance mechanisms clearly underscore the need of developing novel chemical entities, exhibiting higher efficacy and minor side effects.
During our ongoing research concerning the identification of new compounds endowed with anticancer activity (2-11), we investigated the properties of 1,2,5-oxadiazole derivatives. Among them, MD77 (N-[4-(4-chloro-phenyl)-1,2,5-oxadiazol-3-yl]-4-trifluoromethyl-benzamide 1, Figure 1 ) showed a good antiproliferative activity profile against a panel of 58 tumor cell lines derived from 9 cancer cell types (GI50 values ranging from 6.75×10 -6 M against renal cancer cell TK10, to 5.46×10 -7 M, leukemia, HL60TB), and showed Tumor Growth Inhibition (TGI) values lower than 1.00×10 -4 M in most of the cancer cell lines (3) . Therefore, with the aim to integrate the previously obtained data (2), we decided to investigate the effects of phenyl ring substitutions on the antiproliferative activity, by designing ( Figure 1 ) and synthesizing ( Figure 2 ) several compounds related to 1 (2-12), to complete our library (2). Some compounds showed on the phenyl rings the same substituents of 1 but at different positions, while others were substituted with a trifluoromethyl group or with a chlorine atom.
All compounds were tested against HCT116 and HeLa cell lines. Since isomer 4 showed the most interesting growth inhibition results, we also explored its effect on the cellular viability of breast cancer cells (MCF-7 and MDA-MB 468), and the outcomes confirmed the encouraging trend of activity.
We also investigated its mechanism of action using as probes its derivatives 20 (Figure 3 ), bearing fluorescent moieties, and observing their behavior into the cells. Finally, preliminary studies were performed to explore its potential molecular targets.
Materials and Methods
Chemistry. Reagents and solvents were all purchased from Sigma-Aldrich (Saint Louis, MO, USA), except for Oregon Green 488 carboxylic acid succinimide ester obtained from Thermo Fisher Scientific (Waltham, MA, USA), and were used without further purification. Anhydrous solvents were used without further drying. Reactions, performed in conventional conditions or by a microwave synthesizer (Biotage® Initiator; Biotage, Upsala, Sweden) were monitored by thin-layer chromatography on aluminum-backed Silica Gel 60 plates (70-230 mesh; Merck, Darmstadt, Germany), using an ultraviolet fluorescent lamp at 254 nm and 365 nm. Visualization was supported by opportune staining reagents.
Purification of intermediates and final compounds was performed via flash column chromatography on
Geduran Si 60 (40-63 μm, Merck). All the tested compounds were characterized by means of 1 H and 13 C NMR spectra on a Varian Oxford 300 MHz instrument (Palo Alto, CA, USA), equipped with a nonreverse probe at 25°C, operating at 300 MHz for 1 H, 75 MHz for 13 C and 282 MHz for 19 F. Chemical shifts are expressed as δ (ppm) from tetramethylsilane resonance in the indicated solvent (TMS: δ=0.0 ppm). The coupling constants (J-values) are expressed in Hertz (Hz). All spectroscopic data match the assigned structures. Melting points were determined in open capillary tubes on a Buchi Melting Point B-540 (Buchi, Flawil, Switzerland). Mass spectrometry analyses were carried out on an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) equipped with a Finnigan IonMax Electrospray interface. The purity of the compounds was checked by HPLC analysis (≥95%).
The synthesis of 4-bromo and 4-methyl benzoyl chlorides was performed following the procedure reported in literature (2).
Synthesis of 1,2,5-oxadiazol-3-amines 17a-g. The amines 17a-g were obtained as previously described General procedure for the synthesis of amides 6, 10, 11 and 18. To a suspension of NaH 60% dispersion in mineral oil (0.3 mmol) in dry N-N-dimethylformamide (3 ml) cooled on an ice bath under nitrogen atmosphere, the appropriate 4-substuituted phenyl-1,2,5-oxadiazol-3-amine (0.25 mmol) was added, and the mixture was stirred at 0°C for 20 min. Subsequently, the suitable acyl chloride (0.3 mmol) was added dropwise at 0°C and the mixture was stirred at 60°C for 12 h. After the addition of water (3 ml), N-N-dimethylformamide was removed under reduced pressure and the obtained residue was extracted with ethyl acetate (3× 2 ml). The organic phase was dried over Na2SO4 and evaporated under vacuum to obtain the crude product, which was purified by flash column chromatography (eluent mixture: cyclohexane/ethyl acetate, 80:20). (6) . Starting compounds: 17c and 4methylbenzoyl chloride. Yield: 24% as brown solid (m.p.: 163.5-164.0°C). 1 (10) . Starting compounds: (11) . Starting compounds: 
4-(4-methylphenyl)-1,2,5-oxadiazol-3-amine (17b

4-methyl-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide
4-trifluoromethyl-N-(4-(4-bromophenyl)-1,2,5-oxadiazol-3-yl)benzamide
. 4-trifluoromethyl-N-(4-(4-methylphenyl)-1,2,5-oxadiazol-3-yl)benzamide
Synthesis of 2-amino-4-chloro-N-(4-(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazol-3-yl)benzamide (19)
To a solution of benzamide 18 (0.242 mmol) in ethyl acetate (15.61 ml), SnCl2 (1.212 mmol) was added and the mixture was refluxed for 3 h. A saturated aqueous solution of NaHCO3 was added until pH 7-8 and the precipitated tin salts were filtered. The aqueous phase was extracted with ethyl acetate (3 × 3 ml 
phthalamic acid mixture (20) . Oregon Green 488 carboxylic acid succinimide ester (0.078 mmol) was added to a solution of amine 19 (0.078 mmol) and N-N-diisopropylethylamine (0.39 mmol) in dry N-N-dimethylformamide (12 ml), and the mixture was stirred for 5 h at room temperature (12) . After the removal of dimethylformamide under vacuum, the residue was initially filtered on silica and then Cytotoxicity screening. The cytotoxicity of the compounds was determined by MTT assay (13, 14) .
Briefly, the cells were seeded into 96-well plates and cultured overnight. Various concentrations of the test compounds dissolved in DMSO were then added and incubated for 48 h. After incubation, 10% v/v of a solution of 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich) was added and then incubated at 37°C for 3 h. The medium was removed and 100 μl DMSO were added to dissolve the dark blue crystals. After incubation for 30 min at room temperature to ensure the dissolution of all crystals, absorbance was measured using an ELISA plate reader (TECAN, Männedorf, Switzerland) at 595 nm (2).
Antiproliferative assay on HeLa cell line
Cell line culture. The human cervix adenocarcinoma cell line HeLa was grown in Nutrient Mixture F- 12 [HAM] (Sigma Chemical Co., St. Louis, MO USA) supplemented with 10% Heat-inactivated fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Sigma Chemical Co., St. Louis, MO USA). The cells were cultured at 37°C in a moist atmosphere of 5% carbon dioxide in air (11) .
Cytotoxicity screening. HeLa (4-5 × 10 4 ) cells were seeded into a 24-well cell culture plate. After incubation for 24 h, various concentrations of the test agents were added, and the cells were further incubated in standard conditions for 48 h. A trypan blue assay (15) was performed to determine cell viability. Cytotoxicity data were expressed as GI 50 values, i.e. the concentration of the test agent inducing a 50% reduction in the cell count, compared to control cultures (11) . the cells were exposed to a medium containing a serial dilution of compound 4. After a 48-h incubation, cell viability was determined using the resazurin viability fluorometric cell viability kit (PromoCell GmbH, Heidelberg, Germany) according to the manufacturer's instruction. Fluorescence was detected using the TECAN Infinite M200Pro plate reader (Ex=530 nm, Em=590 nm). Viability was calculated as fold of solvent control, after subtracting the fluorescence of the medium. Data were plotted using Graph Pad Prism (version 6.07, La Jolla, CA, USA); the inhibitory potency was estimated calculating the GI50 value using a nonlinear fit regression.
MeT-5A inhibition growth assay. MeT-5A (human mesothelium) cells were grown in RPMI-1640 (Sigma Chemical Co.), supplemented with 2.4 g/l Hepes, 0.11 g/l Na-pyruvate, 2.5 g/l glucose, 2g/l Nabicarbonate. Heat-inactivated FCS 10%, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Sigma Chemical Co.) were added to the medium. The cells were cultured at 37 °C in a moist atmosphere of 5% carbon dioxide in air. Cells (3×10 4 ) were seeded into a 24-well cell culture plate. After incubation for 24 h, various concentrations of the test agents were added to the complete medium and the cells were further incubated for 48 h. A trypan blue assay was performed to determine the cell viability. Cytotoxicity data were expressed as GI50 values, i.e., the concentration of the test agent inducing 50% reduction in the number of cancer cells, compared to control cultures. Fluorescence microscopy. Fluorescence microscopy was performed using an inverted fluorescent microscope Leica DM IL LED (Heerbrugg, Switzerland). Briefly, MCF-7 cells were fixed in paraformaldehyde 4% for 15 min at room temperature. After three washes in phosphate buffer saline (PBS) at pH 7.4, cells were stained first with phalloidin 555 (Thermo Fischer, Zug, Switzerland) for 20 min and then with Hoechst 33342 (Thermo Fisher) for 10 min. All cells were co-stained with phalloidin 555 (staining F-actin of the cytoskeleton) and Hoechst 33342 (staining DNA). Three final washes were then performed before mounting the glass slides, and then fluorescent microscopy was performed.
Images were taken using the software Leica suite X (LASX), and they were analyzed using the Image Processing Software.
Topoisomerase-mediated DNA relaxation assay. Supercoiled pBR322 plasmid DNA (0.25 µg;
Fermentas Life Sciences, Burlington, Ontario, Canada) was incubated with 1 U topoisomerase II (human recombinant topoisomerase II α; USB Corporation, Cleveland, OH, USA) and the test compounds as indicated, for 60 min at 37°C in 20 µl reaction buffer. Reactions were stopped by adding 4 µl stop buffer (5% sodium dodecyl sulfate (SDS), 0.125% bromophenol blue, and 25% glycerol), 50 µg/ml proteinase K (Sigma-Aldrich) and were further incubated for 30 min at 37°C. The samples were separated by electrophoresis on a 1% agarose gel at room temperature. The gels were stained with ethidium bromide 1 µg /ml in TAE buffer (0.04 M Tris-acetate and 0.001 M EDTA) and transilluminated by UV light; fluorescence emission was visualized by a CCD camera, coupled to a Bio-Rad Gel Doc XR apparatus (11) .
Statistical analysis. For statistical analysis, the software GraphPad Prim was used. For statistical analysis of the cell viability the One-way ANOVA with Dunett's multi comparison test was used. The two-way ANOVA was applied for statistical analysis of the cell counting, while two data points comparing the GI50-values was analyzed using an unpaired t-test. A p-value <0.05 was considered statistically significant.
Results and Discussion
Chemistry. Our library of 1,2,5-oxadiazole derivatives, including the previously reported products 1-4, 7-9, 12, was integrated with the new analogues 5, 6, 10, 11, obtained following the synthetic pathway described in the literature, and depicted in Figure 2 (2). Compound 20 was afforded as a mixture of regioisomers, as described in Figure 3 .
The suitable commercially available benzaldehydes were treated with hydroxylamine to give oximes 13a-g, which were then converted into the corresponding chloro-oximes 14a-g in the presence of N-chlorosuccinimide. The chlorine atom was substituted with a cyano group by treatment with potassium cyanide (15a-g). Intermediates 15a-g were reacted in the presence of hydroxylamine to afford the corresponding amino-bis-oximes (acetamidines) 16a-g that were cyclized in basic condition to the amines 17a-g (16) . The latter were coupled with the suitable benzoyl chlorides in the presence of sodium hydride to afford the products 1-12 and the amide 18 (Figure 2) (2). Finally, the nitro group of AlphaScreen-based assay. Several literature works have reported that oxadiazole-based derivatives can inhibit the signal transducer and activator of transcription 3 (STAT3) transcription factor, by binding to its SH2 domain (10, (17) (18) (19) . Therefore, the potential inhibitory activity of the most interesting compounds (1,2 and 4) was tested at 30 µM concentration by an AlphaScreen-based assay, though without positive results (data not shown).
Topoisomerase-mediated DNA relaxation assays. Some oxadiazole derivatives have also been reported to have inhibitory activity on topoisomerases (20, 21) , so the same three compounds, endowed with the highest antiproliferative activity (1, 2 and 4) , were tested against topoisomerase II (Table II) .
All the tested compounds showed an interesting inhibitory effect on topoisomerase II relaxation activity: the results of the assay revealed a complete enzyme inhibition at a concentration of 100 μM.
Conclusions
To gain new insights into the effect of phenyl substitution on the antiproliferative properties of the previously reported compound 1, a small set of oxadiazoles was synthesized and tested on different human tumor cell lines. Among the synthesized derivatives, compounds 2 and 4 showed the most interesting antiproliferative activity, highlighting that only slight modifications on compound 1, such as the shift of the CF3 group to the meta position (2) or the inversion of the position of the substituents (4), are well tolerated. Interestingly, the antiproliferative effect of 4 on non-tumorigenic MeT-5A cells appeared lower with respect to that exerted on tumor cells, suggesting a certain specificity. Further preliminary studies suggested that the antiproliferative properties of this compound could be related to the interaction with microtubules and to the ability to inhibit the relaxation activity of topoisomerase II.
Therefore, these results confirm that compound 4 could be considered as a promising antiproliferative agent, endowed with a good specificity for the tested cancer cell lines. 
